Sunny Pharmtech Inc. (TPEX:6676)

Sunny Pharmtech Statistics

Total Valuation

Sunny Pharmtech has a market cap or net worth of TWD 2.08 billion. The enterprise value is 2.44 billion.

Market Cap	2.08B
Enterprise Value	2.44B

Important Dates

The next estimated earnings date is Friday, April 17, 2026.

Earnings Date	Apr 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Sunny Pharmtech has 148.82 million shares outstanding. The number of shares has increased by 0.66% in one year.

Current Share Class	148.82M
Shares Outstanding	148.82M
Shares Change (YoY)	+0.66%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	17.52%
Owned by Institutions (%)	3.56%
Float	105.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.18
PB Ratio	2.33
P/TBV Ratio	2.50
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-9.07
EV / Sales	8.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-16.76

Financial Position

The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.49.

Current Ratio	1.30
Quick Ratio	0.55
Debt / Equity	0.49
Debt / EBITDA	n/a
Debt / FCF	-3.00
Interest Coverage	-26.09

Financial Efficiency

Return on equity (ROE) is -26.20% and return on invested capital (ROIC) is -10.98%.

Return on Equity (ROE)	-26.20%
Return on Assets (ROA)	-10.05%
Return on Invested Capital (ROIC)	-10.98%
Return on Capital Employed (ROCE)	-20.38%
Revenue Per Employee	1.84M
Profits Per Employee	-1.71M
Employee Count	154
Asset Turnover	0.18
Inventory Turnover	1.16

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.33% in the last 52 weeks. The beta is -0.08, so Sunny Pharmtech's price volatility has been lower than the market average.

Beta (5Y)	-0.08
52-Week Price Change	-35.33%
50-Day Moving Average	14.13
200-Day Moving Average	15.52
Relative Strength Index (RSI)	49.92
Average Volume (20 Days)	138,565

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sunny Pharmtech had revenue of TWD 290.18 million and -269.51 million in losses. Loss per share was -1.82.

Revenue	290.18M
Gross Profit	155.48M
Operating Income	-254.01M
Pretax Income	-269.51M
Net Income	-269.51M
EBITDA	-137.79M
EBIT	-254.01M
Loss Per Share	-1.82

Balance Sheet

The company has 77.93 million in cash and 437.79 million in debt, giving a net cash position of -359.86 million or -2.42 per share.

Cash & Cash Equivalents	77.93M
Total Debt	437.79M
Net Cash	-359.86M
Net Cash Per Share	-2.42
Equity (Book Value)	894.85M
Book Value Per Share	6.01
Working Capital	74.91M

Cash Flow

In the last 12 months, operating cash flow was -112.58 million and capital expenditures -33.23 million, giving a free cash flow of -145.81 million.

Operating Cash Flow	-112.58M
Capital Expenditures	-33.23M
Free Cash Flow	-145.81M
FCF Per Share	-0.98

Margins

Gross margin is 53.58%, with operating and profit margins of -87.53% and -92.88%.

Gross Margin	53.58%
Operating Margin	-87.53%
Pretax Margin	-92.88%
Profit Margin	-92.88%
EBITDA Margin	-47.48%
EBIT Margin	-87.53%
FCF Margin	n/a

Dividends & Yields

Sunny Pharmtech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.66%
Shareholder Yield	-0.66%
Earnings Yield	-12.94%
FCF Yield	-7.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Sunny Pharmtech has an Altman Z-Score of 2.24 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.24
Piotroski F-Score	2